Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Long term impact of maternal opioid use and management strategies on neurodevelopment in rodent offspring

Award Number: U01DA064170
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 02/28/2031

Group Awards By:

View Award Description

Long term impact of maternal opioid use and management strategies on neurodevelopment in rodent offspring - Project Summary The overall goal of this project is to evaluate the long-term impact of in utero oxycodone exposure, opioid maintenance therapy and opioid-withdrawal mitigation strategies on neuro-behavioral development, brain structure and volume and reward processing. Clinical studies have shown concerning long-term, neurodevelopmental outcomes associated with in utero opioid exposure, which include lower social competence scores, memory deficits, and increased risk for behavioral problems and hyperactivity disorders. Clinical data is limited due to a number of challenges, including quality of maternal-infant bonding and care, maternal poly- substance use, epigenetic influences, and socio-economic factors. Given these limitations there is a unique opportunity for mammalian experimental models to investigate the long term effects of in utero opioid exposure, maintenance replacement therapy, as well as opioid withdrawal mitigation treatments on neurobehavioral outcomes. In the first aim we will evaluate the impact of opioid maintenance therapies (methadone and buprenorphine) on offspring, following in utero exposure to oxycodone in dams extending from conception to parturition or through pup weaning. We will also characterize the long-term behavioral impact of clinically- approved opioid withdrawal mitigation treatments, methadone and morphine, as well as buprenorphine in pups, following in utero exposure to oxycodone. In the second aim we will look to correlate changes in brain structure and volume using magnetic resonance imaging in pups following the opioid maintenance therapy in the dams as well as opioid withdrawal mitigation strategies in the pups. In the final aim we will examine whether prenatal opioid exposure and opioid maintenance or withdrawal mitigation strategies disrupt reward processing at the circuit level by examining GABAergic projections from the ventral tegmental area to the nucleus accumbens shell that we have previously shown to modulate reward behavior. Together, this approach will allow us to determine the long-term neuro-behavioral and anatomical changes that occur following in utero oxycodone-exposed pups following: 1) Opioid maintenance therapies in dams and 2) opioid withdrawal mitigation treatments in pups. We hypothesize, that this will impair learning, alter social and reward behavior, induce anxiety- and depressive- related behaviors, and reduce sensitivity to tactile and pain sensation (aim 1); decrease volume in a number of brain regions involved in reward processing and cognitive function such as the basal ganglia, thalamus, hippocampus and amygdala, change amygdalar functional connectivity as well as cause microstructural damage in the corpus callosum (aim 2); increase rewarding valance of GABAergic projection from the ventral tegmental area to the nucleus accumbens shell (aim 3). We hypothesize that exposure to buprenorphine may improve these outcomes due it’s activity at the kappa opioid receptor system. Understanding the long-term impact of oxycodone exposure in tandem with opioid maintenance therapy and opioid withdrawal mitigation strategies will allow us to explore treatment strategies and/or targets that may limit these long-term negative consequences.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $733,457 )
2026	2026	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Drug Use and Addiction Research Programs	000	1	4/13/2026	NEW	$733,457
														Subtotal = $733,457

Grand Total All Awards = $733,457

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Long term impact of maternal opioid use and management strategies on neurodevelopment in rodent offspring

Award Number: U01DA064170

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 02/28/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer